1.
465例Ⅰ期NSCLC患者临床特征
Clinical characteristics of 465 patients with stage Ⅰ NSCLC
| Characteristic | Ⅰa (n=284) | P | Ⅰb (n=181) | P | |||
| Observation (n=241) |
Chemotherapy (n=43) |
Observation (n=115) |
Chemotherapy (n=66) |
||||
| NSCLC: non-small cell lung cancer. | |||||||
| Sex | 0.509 | 0.168 | |||||
| Male | 122 (50.6%) | 19 (44.2%) | 63 (54.8%) | 29 (43.9%) | |||
| Female | 119 (49.4%) | 24 (55.8%) | 52 (45.2) | 37 (56.1%) | |||
| Age (yr) | 0.307 | 0.000 | |||||
| 30-49 | 31 (12.9%) | 5 (11.6%) | 12 (10.4%) | 16 (24.2%) | |||
| 50-69 | 146 (60.6%) | 16 (72.1%) | 50 (43.5%) | 40 (60.6%) | |||
| ≥70 | 64 (26.5%) | 35 (16.3%) | 53 (46.1%) | 10 (15.2%) | |||
| Tumor location | 0.052 | 0.193 | |||||
| Upper right lobe | 103 (42.7%) | 15 (34.9%) | 32 (27.8%) | 23 (34.8%) | |||
| Middle right lobe | 18 (7.5%) | 6 (14.0%) | 9 (7.8%) | 11 (16.7%) | |||
| Lower right lobe | 31 (12.9%) | 11 (25.6%) | 27 (23.5%) | 13 (19.7%) | |||
| Upper left lobe | 52 (21.6%) | 9 (20.9%) | 25 (21.7%) | 13 (19.7%) | |||
| Lower left lobe | 37 (15.4%) | 2 (4.7%) | 19 (16.5%) | 6 (9.1%) | |||
| Endobronchial | / | / | 3 (2.6%) | 0 (0.0%) | |||
| Histologic type | 0.637 | 0.877 | |||||
| Adenosquamous | 3 (1.2%) | 1 (2.3%) | 1 (0.9%) | 1 (1.5%) | |||
| Squamous | 23 (9.5%) | 6 (14.0%) | 22 (19.1%) | 11 (16.7%) | |||
| Adenocarcinoma | 204 (84.6%) | 33 (76.7%) | 86 (74.8%) | 49 (74.2%) | |||
| Neuroendocrine | 11 (4.6%) | 3 (7.0%) | 6 (5.2%) | 5 (7.6%) | |||
| Resection range | 0.439 | 0.888 | |||||
| Wedge or segment | 29 (12.0%) | 3 (7.0%) | 13 (11.3%) | 6 (9.1%) | |||
| Lobectomy | 212 (88.0%) | 40 (93.0%) | 99 (86.1%) | 58 (87.9%) | |||
| Pneumonectomy | / | / | 3 (2.6%) | 2 (3.0%) | |||
| or double | |||||||
| lobectomy | |||||||
| Differentiation degree | 0.538 | 0.680 | |||||
| Unknown | 27 (11.2%) | 5 (11.6%) | 6 (5.2%) | 1 (1.5%) | |||
| High | 66 (27.4%) | 7 (16.3%) | 8 (7.0%) | 7 (10.6%) | |||
| Middle-high | 44 (18.3%) | 9 (20.9%) | 22 (19.1%) | 9 (13.6%) | |||
| Middle | 65 (27.0%) | 11 (25.6%) | 45 (39.1%) | 27 (40.9%) | |||
| Low-middle | 21 (8.7%) | 5 (11.6%) | 22 (19.1%) | 14 (21.2%) | |||
| Low | 18 (7.5 %) | 6 (14.0%) | 12 (10.4%) | 8 (12.1%) | |||
| Tumor diameter (cm) | 0.056 | 0.264 | |||||
| 0＜d≤1 | 87 (36.1%) | 8 (18.6%) | 20 (17.4%) | 5 (7.6%) | |||
| 1＜d≤2 | 99 (41.1%) | 20 (46.5%) | 40 (34.8%) | 22 (33.3%) | |||
| 2＜d≤3 | 55 (22.8%) | 15 (34.9%) | 31 (27.0%) | 22 (33.3%) | |||
| 3＜d≤4 | / | / | 24 (20.9%) | 17 (25.8%) | |||
| Visceral pleural invasion | / | 0.604 | |||||
| Negative | / | / | 29 (25.2%) | 19 (28.8) | |||
| Positive | / | / | 86 (74.8%) | 47(71.2) | |||
| Vascular invasion | 0.110 | 0.174 | |||||
| Negative | 239 (99.2%) | 41 (95.3%) | 111 (96.5%) | 60 (90.9%) | |||
| Positive | 2 (0.8%) | 2 (4.7%) | 4 (3.5%) | 6 (9.1%) | |||